

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(**深圳市海普瑞藥業集團股份有限公司**)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(**Stock Code: 9989**)

VOLUNTARY ANNOUNCEMENT

**THE GROUP'S ENOXAPARIN SODIUM INJECTION
OBTAINS MARKETING APPROVAL FROM
NATIONAL PHARMACOLOGY COMMITTEE OF BOLIVIA**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Compan²**”, together with its subsidiaries referred to as the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Shenzhen Techdow Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, which is a supplier to produce Enoxaparin sodium injection product, Novonox, has obtained the marketing approval from National Pharmacological Commission of Bolivia.

DETAILS OF THE DRUG

- (I) Drug brand: Novonox
- (II) Novonox (enoxaparin) is indicated for:

The prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing:

- orthopedic surgery of the hip or knee; In addition, Novonox is indicated in hospital or after hospital discharge for long-term prevention of venous thromboembolic diseases following hip replacement surgery.
- high risk abdominal, gynecological, or urological surgeries
- colorectal surgery

The prophylaxis of deep vein thrombosis (DVT) in medical patients who are at moderate risk of DVT and who are bedridden due to moderate to severe acute cardiac insufficiency (NYHA Class III or IV heart failure), acute respiratory failure revealing or complicating chronic respiratory insufficiency not requiring ventilatory support and acute respiratory infections (excluding septic shock), who require short-term prophylaxis of deep vein thrombosis.

The prevention of thrombus formation in the extra-corporeal circulation during hemodialysis.

Novonox is also indicated for:

The treatment of deep vein thrombosis, with or without pulmonary embolism.

The treatment of unstable angina or non-Q-wave myocardial infarction, concurrently with ASA.

Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI), including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI).

(III) Dosage form: Solution for injection

(IV) Strength:

Novonox: 40mg/0.4ml, 60mg/0.6ml

(V) Registration Category: Prescription drug

BENEFITS AND IMPACTS TO THE COMPANY

Currently, the enoxaparin sodium injection products of the Group, have been approved in more than 50 countries for sales in the market around the world. The Board believes that those good feedbacks of sales and safety data in overseas markets over the past three years has enabled the Group to obtain more market share, and the Board expects that this registration approval will further accelerate the global layout advancement of the Company's finished dose pharmaceutical business.

Announcement is hereby given.

By order of the Board
Shen hen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC

June 7, 2021

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.